Q3 Earnings Estimate for Climb Bio Issued By William Blair

Climb Bio, Inc. (NASDAQ:CLYM) – Investment analysts at William Blair issued their Q3 2025 earnings estimates for shares of Climb Bio in a research report issued to clients and investors on Thursday, October 16th. William Blair analyst M. Phipps forecasts that the company will post earnings of ($0.14) per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Climb Bio’s current full-year earnings is ($1.57) per share. William Blair also issued estimates for Climb Bio’s Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.72) EPS, FY2026 earnings at ($0.73) EPS, FY2027 earnings at ($0.88) EPS, FY2028 earnings at ($1.09) EPS and FY2029 earnings at ($1.47) EPS.

Several other research firms have also weighed in on CLYM. BTIG Research reaffirmed a “buy” rating and issued a $8.00 target price on shares of Climb Bio in a report on Thursday. Wall Street Zen raised shares of Climb Bio from a “sell” rating to a “hold” rating in a report on Monday, October 6th. HC Wainwright started coverage on shares of Climb Bio in a report on Monday, October 13th. They issued a “buy” rating and a $9.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Climb Bio in a report on Wednesday, October 8th. Finally, Robert W. Baird started coverage on shares of Climb Bio in a report on Friday, August 15th. They set an “outperform” rating and a $9.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $9.20.

Climb Bio Stock Performance

CLYM opened at $1.93 on Monday. The firm’s 50-day simple moving average is $2.10 and its 200-day simple moving average is $1.58. Climb Bio has a twelve month low of $1.05 and a twelve month high of $5.10. The firm has a market cap of $130.78 million, a price-to-earnings ratio of -2.76 and a beta of -0.07.

Climb Bio (NASDAQ:CLYM) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.06.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CLYM. Bank of New York Mellon Corp acquired a new position in Climb Bio during the 1st quarter valued at about $79,000. Peapod Lane Capital LLC acquired a new position in Climb Bio during the 1st quarter valued at about $676,000. TD Asset Management Inc acquired a new stake in shares of Climb Bio in the 1st quarter valued at approximately $109,000. XTX Topco Ltd acquired a new stake in shares of Climb Bio in the 1st quarter valued at approximately $34,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of Climb Bio in the 1st quarter valued at approximately $86,000. 69.76% of the stock is currently owned by institutional investors and hedge funds.

Climb Bio Company Profile

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.